IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma.
Gérard Zalcman, J. Margery, Arnaud Scherpereel et al. · Journal of Clinical Oncology · 2010
7020 Background: MPM median OS does not exceed 13 months with pem/CDDP doublet. U.S. Intergroup phase II trial of gemcitabine/CDDP, with or without bevacizumab, gave an appealing 15.6 months median OS in the bevacizumab arm. French Intergroup aimed to test pem/CDDP with bevacizumab (PCB), in a randomized phase II-III trial. Methods: Eligible patients had unresectable histologically proved MPM, no prior chemo, PS 0-2, no thrombosis, nor bleeding. Primary endpoint: % of nonprogressive patients at 6 months. Statistics: H0: p ≤ 40% vs. H1: P ≥ 60%; binomial exact test: 50 assessable patients in each arm, and 25 nonprogressive patients in the bevacizumab arm to begin the phase III (94.3% Power, α=9.8%). Patients received pem 500 mg/m2, CDDP 75 mg/m2 (PC),at D1, with (arm B) or without bevacizumab (arm A), 15 mg/kg Q21D, for 6 cycles. Arm B non- rogressive patients received bevacizumab maintenance therapy until progression or toxicity. Enrollment was achieved within 24 months in 53 French centers. Results: On January 7, 2010, 111 patients were enrolled. Med.age: 64.3 (34.7-75.5), M:F = 80:31, epithelioid:sarcomatoid/mixt = 90:21, WHO PS 0:1:2 = 49:57:5. In the 72 first patients reaching 6 months evaluation, 455 cycles of chemotherapy have been analyzed. 11/72 patients (15.3%) had grade 4 events related to chemotherapy. There was no significant difference in grade 3/4 toxicity between the two arms. AE are presented in the Table (max. toxicity for each patient). In the first 71 assessable patients (1 noneligible), there were 25/34 patients (73.5%) with DC (1 CR, 15 PR, 9 stable disease) in Arm B vs. 16/37 (43.2%) in arm A (p=0.010). Conclusions: PCB chemo was well-tolerated and feasible. The statistical endpoint of the phase II study has been reached. Updated toxicity data, PFS, and DCR at 6 months will be presented at the Meeting. Arm A % Arm B % Grade 3 % Grade 4 Grade 3 % Grade 4 n = 37 n = 37 n = 35 n = 35 Anorexia 3 8.1% 0 0 0 Asthenia 6 16.2% 0 5 14.3% 0 Pulmonary embolism 0 0 0 2.8% 3 8.6% Hypertension 0 0 3 8.6% 0 Neutropenia 14 37.8% 3 8.1% 12 34.3% 4 11.4% Febrile neutropenia 1 2.7% 0 0 2.8% 0 Thrombopenia 0 10.8% 0 2.7% 0 2.8% 0 Vomiting 0 5.4% 0 0 5.6% 0 2.8% Creatinine increase 0 0 3 8.6% 0 Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca, GlaxoSmithKline, Lilly, Roche AstraZeneca, GlaxoSmithKline, Lilly, Merck Serono, MSD France, Roche Lilly, Roche Lilly, Roche
Cited by 34 works. doi:10.1200/jco.2010.28.15_suppl.7020